Royalty Pharma (RPRX)Officer sold ~$4.38M

~$4.38M

Approx. value · 110K sh @ $39.77

110K

Holds after · shares reported

Traded

Dec 3, 2025

Filed

Dec 6, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 5, 2025Company filing · Form 8-K · ResultsReported its results
2. Nov 17, 2025Insider · 1 personInsiders: 2 sales (~$2.7M)
3. Nov 19, 2025Insider · 1 personInsiders: 8 sales (~$5.2M)
4. Nov 24, 2025Insider · 1 personInsiders: 4 sales (~$2.7M)
5. Dec 1, 2025Insider · 2 peopleInsiders: 4 sales (~$4.4M)
6. Dec 3, 2025 · this disclosureInsiderOfficer sold ~$4.38M of RPRX shares in the open market

What came next

1. Dec 5, 2025Insider · 1 personInsiders: 2 sales (~$1.6M)
2. Dec 15, 2025Insider · 1 personInsiders: 2 sales (~$2.7M)
3. Dec 16, 2025InsiderOfficer sold ~$766K of RPRX shares in the open market
4. Dec 17, 2025InsiderOfficer sold ~$3.06M of RPRX shares in the open market
5. Dec 18, 2025InsiderOfficer sold ~$1.18M of RPRX shares in the open market
6. Dec 19, 2025InsiderOfficer sold ~$768K of RPRX shares in the open market
7. Dec 20, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 20, 2025, George W. Lloyd, age 66, informed Royalty Pharma plc (the “Company”) of his decision to transition from his role of Executive Vice President and Chief Legal Officer effective December 31, 2025.”
8. Dec 26, 2025InsiderOfficer sold ~$786K of RPRX shares in the open market
9. Jan 2, 2026Insider · 2 peopleInsiders: 3 sales (~$3.4M)
10. Jan 9, 2026InsiderOfficer sold ~$816K of RPRX shares in the open market
11. Jan 16, 2026InsiderOfficer sold ~$790K of RPRX shares in the open market
12. Jan 20, 2026Insider · 1 personInsiders: 2 sales (~$2.7M)
13. Jan 23, 2026InsiderOfficer sold ~$805K of RPRX shares in the open market
14. Jan 30, 2026InsiderOfficer sold ~$822K of RPRX shares in the open market
15. Feb 2, 2026Insider · 1 personInsiders: 2 sales (~$4.6M)
16. Feb 3, 2026Insider · 1 personInsiders: 2 sales (~$4.9M)
17. Feb 4, 2026Insider · 1 personInsiders: 2 sales (~$873K)
18. Feb 11, 2026Company filing · Form 8-K · ResultsReported its results
19. Feb 23, 2026Insider · 1 personInsiders: 2 sales (~$1.6M)
20. Mar 2, 2026Insider · 1 personInsiders: 4 sales (~$1.6M)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Royalty Pharma

For Royalty Pharma, OQRO holds 8 insider filings (SEC Form 4 or Form 144) and 7 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RPRX page.

Other recent filings by George W. Lloyd, EVP, Investments & CLO

• SEC Form 4 at Royalty Pharma (RPRX)Dec 20, 2025
• SEC Form 4 at Royalty Pharma (RPRX)Dec 20, 2025
• SEC Form 4 at Royalty Pharma (RPRX)Nov 22, 2025
• SEC Form 4 at Royalty Pharma (RPRX)Nov 22, 2025
• SEC Form 4 at Royalty Pharma (RPRX)Nov 22, 2025

The full history of George W. Lloyd, EVP, Investments & CLO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Royalty Pharma

• SEC Form 4Oct 6, 2026
• SEC Form 144Oct 5, 2026
• SEC Form 4Oct 1, 2026
• SEC Form 4Sep 25, 2026
• SEC Form 4Sep 25, 2026
• SEC Form 4Aug 20, 2026

Everything OQRO holds on this company is on its RPRX page.